Vaxart, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Vaxart, Inc. (VXRT) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $167.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-08-06
- Vaxart, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2026-06-30 was $167.00K, a 4.02% decline year-over-year.
- Vaxart, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-06-30 was $174.00K.
- Vaxart, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-09-30 was $10.00K.
- Vaxart, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2023-03-31 was $103.00K, a 67.20% decline year-over-year.
- Vaxart, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2022 was $786.00K, a 86.34% decline from fiscal 2021.
- Vaxart, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2021 was $5.75M.
- Vaxart, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2019 was $560.00K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 6 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 9 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $167.00K 10-Q · filed 2026-08-06 | $167.00K 10-Q · filed 2026-08-06 | ||
| 2025-06-30 | $174.00K 10-Q · filed 2026-08-06 | $174.00K 10-Q · filed 2026-08-06 | ||
| 2024-09-30 | $10.00K 10-Q · filed 2025-11-13 | |||
| 2023-03-31 | $103.00K 10-Q · filed 2023-05-04 | $306.00K derived: sum of 2 quarters · filed 2023-05-04 | $467.00K derived: sum of 3 quarters · filed 2023-05-04 | $575.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $364.00K derived: sum of 2 quarters · filed 2023-03-15 | $472.00K derived: sum of 3 quarters · filed 2023-03-15 | $786.00K 10-K · filed 2023-03-15 |
| 2022-09-30 | $161.00K 10-Q · filed 2022-11-09 | $269.00K derived: sum of 2 quarters · filed 2022-11-09 | $583.00K 10-Q · filed 2022-11-09 | $583.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $422.00K 10-Q · filed 2022-08-08 | $422.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.17M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $314.00K 10-Q · filed 2023-05-04 | $314.00K derived: sum of 2 quarters · filed 2023-05-04 | $1.06M derived: sum of 3 quarters · filed 2023-05-04 | $2.88M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $746.00K derived: sum of 2 quarters · filed 2023-03-15 | $2.57M derived: sum of 3 quarters · filed 2023-03-15 | $5.75M 10-K · filed 2023-03-15 |
| 2021-09-30 | $746.00K 10-Q · filed 2022-11-09 | $2.57M derived: sum of 2 quarters · filed 2022-11-09 | $5.75M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.82M 10-Q · filed 2022-08-08 | $5.01M 10-Q · filed 2022-08-08 | ||
| 2020-09-30 | $2.97M 10-Q · filed 2020-11-12 | $2.97M 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $1.28M 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $1.58M derived: sum of 3 quarters · filed 2022-02-24 | $560.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.58M derived: sum of 2 quarters · filed 2020-11-12 | $560.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $1.58M 10-Q · filed 2019-08-08 | $560.00K 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $560.00K 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |